CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Penington, D. J.
Right arrow Articles by Riese, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Penington, D. J.
Right arrow Articles by Riese, D. J., II
Cell Growth & Differentiation Vol. 13, 247-256, June 2002
© 2002 American Association for Cancer Research

Constitutively Active ErbB4 and ErbB2 Mutants Exhibit Distinct Biological Activities1

Desi J. Penington, Ianthe Bryant and David J. Riese, II2

Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana 47907-1333

ErbB4 is a member of the epidermal growth factor receptor(EGFR) family of tyrosine kinases, which includes EGFR/ErbB1, ErbB2/HER2/Neu, and ErbB3/HER3. These receptors play important roles both in normal development and in neoplasia. For example, deregulated signaling by ErbB1 and ErbB2 is observed in many human malignancies. In contrast, the roles that ErbB4 plays in tumorigenesis and normal biological processes have not been clearly defined. To identify the biological responses that are coupled to ErbB4, we have constructed three constitutively active ErbB4 mutants. Unlike a constitutively active ErbB2 mutant, the ErbB4 mutants are not coupled to increased cell proliferation, loss of contact inhibition, or anchorage independence in a rodent fibroblast cell line. This suggests that ErbB2 and ErbB4 may play distinct roles in tumorigenesis in vivo.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
C. K. Goth, A. Halim, S. A. Khetarpal, D. J. Rader, H. Clausen, and K. T.- B. G. Schjoldager
A systematic study of modulation of ADAM-mediated ectodomain shedding by site-specific O-glycosylation
PNAS, November 24, 2015; 112(47): 14623 - 14628.
[Abstract] [Full Text] [PDF]


Home page
Biochem. J.Home page
K. J. Wilson, C. P. Mill, R. M. Gallo, E. M. Cameron, H. VanBrocklin, J. Settleman, and D. J. Riese II
The Q43L mutant of neuregulin 2{beta} is a pan-ErbB receptor antagonist
Biochem. J., April 1, 2012; 443(1): 133 - 144.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
C. Finger, C. Escher, and D. Schneider
The Single Transmembrane Domains of Human Receptor Tyrosine Kinases Encode Self-Interactions
Sci. Signal., September 22, 2009; 2(89): ra56 - ra56.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S.-M. Feng, R. S. Muraoka-Cook, D. Hunter, M. A. Sandahl, L. S. Caskey, K. Miyazawa, A. Atfi, and H. S. Earp III
The E3 Ubiquitin Ligase WWP1 Selectively Targets HER4 and Its Proteolytically Derived Signaling Isoforms for Degradation
Mol. Cell. Biol., February 1, 2009; 29(3): 892 - 906.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
K. E. Strunk, C. Husted, L. C. Miraglia, M. Sandahl, W. A. Rearick, D. M. Hunter, H. S. Earp III, and R. S. Muraoka-Cook
HER4 D-Box Sequences Regulate Mitotic Progression and Degradation of the Nuclear HER4 Cleavage Product s80HER4
Cancer Res., July 15, 2007; 67(14): 6582 - 6590.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
J. A. Maatta, M. Sundvall, T. T. Junttila, L. Peri, V. J. O. Laine, J. Isola, M. Egeblad, and K. Elenius
Proteolytic Cleavage and Phosphorylation of a Tumor-associated ErbB4 Isoform Promote Ligand-independent Survival and Cancer Cell Growth
Mol. Biol. Cell, January 1, 2006; 17(1): 67 - 79.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
C. V. Lund, M. Popkov, L. Magnenat, and C. F. Barbas III
Zinc Finger Transcription Factors Designed for Bispecific Coregulation of ErbB2 and ErbB3 Receptors: Insights into ErbB Receptor Biology
Mol. Cell. Biol., October 15, 2005; 25(20): 9082 - 9091.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. A. Alaoui-Jamali, D. J. Song, N. Benlimame, L. Yen, X. Deng, M. Hernandez-Perez, and T. Wang
Regulation of Multiple Tumor Microenvironment Markers by Overexpression of Single or Paired Combinations of ErbB Receptors
Cancer Res., July 1, 2003; 63(13): 3764 - 3774.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 2002 by the American Association of Cancer Research.